Zalunfiban dihydrochloride

• CAT Number: I045547
• CAS Number: 2815778-41-5
• Molecular Formula: C16H20Cl2N8O2S
• Molecular Weight: 459.35
• Purity: ≥95%
• Synonyms: 2-amino-N-[5-(5-oxo-7-piperazin-1-yl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyridin-3-yl]acetamide;dihydrochloride
• InChI: InChI=1S/C16H18N8O2S.2ClH/c17-7-13(25)20-11-5-10(8-19-9-11)15-22-24-14(26)6-12(21-16(24)27-15)23-3-1-18-2-4-23;;/h5-6,8-9,18H,1-4,7,17H2,(H,20,25);2*1H
• InChIKey: GVDRCFLSNUIMCT-UHFFFAOYSA-N
• SMILES: C1CN(CCN1)C2=CC(=O)N3C(=N2)SC(=N3)C4=CC(=CN=C4)NC(=O)CN.Cl.Cl

Zalunfiban dihydrochloride (Cat No.: I045547) is a potent, small-molecule αIIbβ3 integrin (GPIIb/IIIa) antagonist under investigation as an antithrombotic agent. By blocking fibrinogen binding to platelet αIIbβ3 receptors, it inhibits platelet aggregation, thereby reducing thrombus formation. Designed for rapid, subcutaneous administration, Zalunfiban offers advantages over intravenous GPIIb/IIIa inhibitors, making it a promising candidate for the early treatment of acute coronary syndromes (ACS). In research, it is employed to study platelet biology, integrin signaling, and novel antiplatelet therapeutic strategies.

Reference

[1]. Vootukuri S, et al. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019;3(2-3):65-74.
[Content Brief]